FDA’s recent efforts to combat opioid-related adverse events, abuse and death include revisiting some old ideas, such as prescriber education, risk management plans and labeling changes.
However, two University of Washington researchers are making the case for a new and heightened level of agency oversight
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?